Alzheimer's disease is characterized by amyloid peptide formation and deposition, neurofibrillary tangles, synaptic loss and central cholinergic dysfunction, dysfunction of energy metabolism, and dementia; however, the interactions between these hallmarks remain poorly defined. We studied a well characterized mouse model of amyloid deposition, the doubly transgenic APP SWE ϫPSEN1dE9 mouse. At 10 to 14 months of age, these mice had high levels of amyloid peptides (6.6 g/g wet weight) and widespread amyloid plaques. Extracellular levels of acetylcholine (ACh) were determined by microdialysis in the hippocampus and were comparable with nontransgenic mice from the same colony. In the open field, both mouse strains responded with a 3-fold increase of hippocampal ACh release. Exploratory behavior of the transgenic mice appeared normal. Infusion of scopolamine evoked 5-to 6-fold increases of ACh levels in both mouse strains. High-affinity choline uptake and cholinesterase activities were identical in both mouse lines. Extracellular levels of glucose and glycerol were similar in control and transgenic mice, whereas lactate levels were slightly (p ϭ 0.06) and glutamate levels significantly (p ϭ 0.02) lower in transgenic mice. Exploration caused increases of glucose and lactate, whereas infusion of scopolamine (1 M) increased glucose but not lactate. Glutamate levels were increased by scopolamine, whereas glycerol remained constant under all the conditions. We conclude that amyloid peptide production and plaque deposition causes minor changes in cholinergic function and energy metabolites in transgenic mice in vivo. Amyloid peptide formation and/or deposition may not be sufficient for long-term cholinergic or metabolic dysfunction.
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Alzheimer's disease (AD) is the most frequent type of dementia in humans and is characterized by cognitive dysfunction and early memory loss (Blennow et al., 2006; Burns and Iliffe, 2009) . AD brains display amyloid plaques and neurofibrillary tangles, as well as neuronal degeneration and generalized atrophy. Cholinergic fibers originating in the basal forebrain and innervating hippocampus and cortex seem to degenerate relatively early in the disease, although the clinical evidence is somewhat controversial (Mesulam, 2006; Schliebs and Arendt, 2006) . In later stages of the disease, cholinergic dysfunction correlates well with dementia, and current therapies of AD use inhibitors of acetylcholinesterase (AChE) to enhance cholinergic transmission in the brain. Although treatment of AD with AChE inhibitors as a monotherapy has only limited effects, successful treatment of dementia will probably not be possible without correcting the cholinergic deficit. Thus, the understanding of the cholinergic dysfunction and its development remains highly relevant for drug treatment of AD.
In clinical studies, AD can be distinguished in early onset disease (familial AD) and late-onset, sporadic disease (Blennow et al., 2006; Burns and Iliffe, 2009) . The rare familial AD cases have mutations in genes coding for amyloid precursor protein (APP) and the presenilins (PSs); both mutations have been shown to cause amyloid peptide formation and amyloid plaque depositions in human brain. These characteristic features have given rise to the "amyloid hypothesis," which postulates that the formation of amyloid peptides is responsible for the etiology of AD (Hardy and Selkoe, 2002) . Therefore, present animal models of AD are largely based on mutations in APP and PS genes (see below). However, it should be noted that the relevance of amyloid peptides and plaque formation for the etiology of the common, "sporadic" form of AD is unclear. Major risk factors for sporadic AD include old age and the presence of apolipoprotein E4 alleles (Blennow et al., 2006) . In addition, metabolic changes, damage to mitochondrial components, and changes of glucose utilization in the brain were observed in sporadic AD (Blass et al., 2002; Eckert et al., 2003; Mosconi et al., 2008) .
Based on the amyloid hypothesis, transgenic mice have been generated that express (usually overexpress) various APP and PS1 genes containing mutations that were identified in human familial AD (McGowan et al., 2006) . Whereas overexpression of human APP mutations in mice produces high levels of amyloid peptides but not overt neuronal loss or behavioral dysfunctions, transgenic mice with double mutations in APP and PS1 genes were associated with various degrees of dysfunction in electrophysiological and behavioral models (McGowan et al., 2006) . Central cholinergic function in these mice has been addressed in a variety of experimental studies (reviewed by Kar et al., 2004; Schliebs and Arendt, 2006) but gave contradictory results. For example, several markers of cholinergic function [choline acetyltransferase, vesicular acetylcholine (ACh) transporter, high-affinity choline uptake (HACU)] were found to be unchanged in Tg2576 mice during aging (Gau et al., 2002) . In contrast, HACU was found to be reduced in aged (21-month-old) Tg2576 mice, whereas the density of the vesicular ACh transporter was increased (Apelt et al., 2002) . In doubly transgenic mice overexpressing human APP and PS mutations, the number of forebrain cholinergic cells was normal, but cholinergic synapse density was decreased (Bell and Cuello, 2006) . In previous work from our group, we observed a small increase of septal cholinergic neurons in a double transgenic APP/PS1 mouse model with moderate amyloid plaque deposition (Hartmann et al., 2004) . Basal ACh levels in the hippocampus were slightly but significantly reduced, whereas stimulated release was unchanged. In contrast, in TgCRND8 mice, which have very high levels of amyloid, basal forebrain neurons showed signs of atrophy and inflammation at age 7 months, and both basal and stimulated ACh release was reduced (Bellucci et al., 2006) .
In the present study, we used microdialysis to study a well known mouse model, the APP SWE ϫ PSEN1dE9 mouse, which is characterized by aggressive amyloid deposition (Borchelt et al., 1997; Jankowsky et al., 2004) . In addition to ACh and cholinergic markers, we monitored extracellular levels of glucose and lactate, two major metabolites reflecting neuronal energy metabolism, and of the neurotransmitter glutamate.
Materials and Methods
Animals. Male B6C3-Tg(APP SWE , PSEN1dE9)85Dbo/J mice and the appropriate controls were obtained from The Jackson Laboratory (JAX004462; Bar Harbor, ME). The transgenic mice were generated by simultaneously coinjecting the transgenic constructs into the founder mouse pronucleus (Jankowsky et al., 2004) ; expression of both genes is controlled by the mouse prion promoter. The mutant mice express APP harboring the Swedish mutation (K594M/N595L) and a presenilin-1 gene in which exon 9 is deleted (PSEN1dE9). Breeding of the transgenic mice occurred as hemizygotes, and the control mice in this study were wild-type mice from the same colony (The Jackson Laboratory). All mice were housed in a facility with controlled temperature and humidity and a day/night cycle of 12/12 h. They had free access to food and water. All of the experiments were approved by the Animal Care and Use Committee at Texas Tech University Health Science Center (Protocol 04030-08).
Mouse behavior was observed in the "open field," a dark gray, rectangular plastic box (45 ϫ 30 ϫ 15 cm). We scored line crossings, rearing, leaning, freezing, and grooming during 3 min of observation as measures of spontaneous behavior.
Reagents. Most chemicals were obtained from Sigma-Aldrich (St. Louis, MO) in the highest purity available. The enzyme-linked immunosorbent assay (ELISA) kit for determination of amyloid peptide was from BioSource International (Camarillo, CA) and was ordered through Invitrogen (Carlsbad, CA); additional chemicals for ELISA (molecular biology grade) and the protease inhibitor mixture were from Calbiochem (La Jolla, CA). [ 3 H]Choline (specific activity, 60 -90 Ci/mmol) was from American Radiolabeled Chemicals (St. Louis, MO), and scintillation mixture for the HACU assay (Scintisafe 30%) was from Thermo Fisher Scientific (Waltham, MA).
Histochemistry. Amyloid plaques were stained in right brain hemispheres of control and transgenic animals as described in Bussière et al. (2004) and visualized on a Nikon (Tokyo, Japan) fluorescence microscope.
Quantification of Amyloid Peptide. Amyloid A␤ 1-42 was quantified using a colorimetric ELISA kit from Invitrogen (BioSource). In brief, cortex and hippocampus from one hemisphere were separated, weighed, and homogenized in 10 volumes of 5 M guanidine HCl/50 mM Tris, pH 8.0, supplemented with protease inhibitor mixture from Calbiochem. The homogenates were frozen at Ϫ20°C. On the day of the assay, homogenates were thawed, diluted 100-fold, and centrifuged (16,000g, 20 min, 4°C). A␤ in the supernatant was quantified according to kit instructions. Each sample was measured in triplicate.
Cholinergic Parameters. Total choline uptake, HACU, and lowaffinity choline uptake were determined in synaptosomal (P 2 ) fractions obtained from cortex and hippocampus as described in a previous publication (Hartmann et al., 2004) . Cholinesterase activities were assessed as described previously (Li et al., 2000) .
Microdialysis Experiments. Mice were anesthetized with isoflurane (induction dose, 4%; maintenance dose, 1-1.5% v/v) in a 25/75% mixture of oxygen and nitrous oxide and placed in a stereotaxic frame. Self-made, I-shaped, concentric dialysis probes with an exchange length of 1 mm were implanted in the right dorsal hippocampus using the following coordinates (from bregma): anteriorposterior, Ϫ2.2 mm; lateral, Ϫ1.8 mm; dorso-ventral, Ϫ2.3 mm. Mice were allowed to recover overnight, and experiments were carried out on 2 consecutive days after probe implantation in freely moving animals.
On the experimental days, the microdialysis probes were perfused with artificial cerebrospinal fluid (aCSF; 147 mM NaCl, 4 mM KCl, 1.2 mM CaCl 2 , and 1.2 mM MgCl 2 ) supplemented with 1 M neostigmine bromide. The perfusion rate was 2 l/min, and efflux from the microdialysis probe was collected in intervals of 15 min. On the first day of microdialysis, samples were collected for 90 min to establish baseline values of ACh. Subsequently, animals were placed into a novel environment, consisting of a dark gray, rectangular plastic box (45 ϫ 30 ϫ 15 cm), termed the open field. After 90 min in the open field, mice were returned to their home cages, and dialysis was continued for 2 h. On the 2nd day, baseline values for ACh were collected again; then the perfusion fluid was switched to aCSF containing 1 M scopolamine bromide. After 90 min, the perfusion fluid was switched back to aCSF, and mice were further monitored for a period of at least 2 h. On day 3 after probe implantation, mice were sacrificed; probe locations were verified; and contralateral hemispheres were extracted for subsequent staining or assessment of amyloid burden by ELISA.
Chemical Analysis of Microdialysates. ACh and choline in dialysates were determined by microbore high-performance liquid chromatography/electrochemical detection using a metal-free system from BAS Bioanalytical Systems (West Lafayette, IN). The procedure was performed as described previously (Kopf et al., 2001; Hartmann et al., 2004) . At an injection volume of 5 l, the detection limit of this system was 5 to 10 fmol/injection. Glucose, lactate, glutamate, and glycerol concentrations in the microdialysis samples were determined by a CMA/Microdialysis (Solna, Sweden) 600 microanalyzer using a kinetic photometric assay as described by the manufacturer.
Statistical Analysis. Data are given as mean Ϯ S.E.M. of n experiments and were compared by Student's t test (Table 1) . Time
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Results
Characterization of Mice. Amyloid formation in APP SWE / PS1dE9 mice was extensively characterized in previous work by the group who created these mice. These doubly transgenic mice have high amyloid peptide levels, and amyloid plaques were already observed at 4 to 6 months of age (Jankowsky et al., 2004; Savonenko et al., 2005; GarciaAlloza et al., 2006) . In the present study, we used these mice at age 10 to 14 months. As expected, these mice had plenty of amyloid plaques that could be visualized with thioflavin S (Fig. 1) . Formation of amyloid peptide A␤ 1-42 was measured by ELISA and yielded a value of 6.6 Ϯ 0.4 g/g wet weight (Table 1) . Control mice had neither amyloid plaques (Fig. 1 ) nor measurable amounts of amyloid peptides.
Cholinergic Parameters. Enzymatic activities of cholinesterases in control mice were AChE, 2.80 Ϯ 0.28 U/g wet weight and butyrylcholinesterase, 0.14 Ϯ 0.02 U/g wet weight (n ϭ 5). In transgenic mice, the values were very similar, and differences between the two groups were not statistically significant (Table 1) . Choline uptake measurements also did not reveal differences between the two groups of mice. HACU, an ex vivo marker for ACh turnover, was identical in both mouse strains (Table 1) . Total choline uptake and low-affinity choline uptake were also unchanged (data not shown).
Microdialysis: ACh and Choline. In control mice, basal efflux was 100.3 Ϯ 12 fmol/5 l for ACh and 2.62 Ϯ 0.31 pmol/5 l for choline (n ϭ 8). After correction for in vitro recoveries (9.6% for ACh and 14.6% for choline), extracellular concentrations for ACh were estimated at 209 nM and for choline at 3.59 M (Table 1 ). In transgenic APP SWE /PS1dE9 mice, basal efflux was 92.4 Ϯ 12 fmol/5 l for ACh and 2.69 Ϯ 0.23 pmol/5 l for choline (n ϭ 8), yielding extracellular concentrations for ACh of 193 nM and 3.69 M for choline in transgenic mice, which were not statistically different from control mice (Table 1) .
Two paradigms were used to stimulate release of ACh, namely, exposure to a novel environment and infusion of scopolamine (see below). When mice were placed into a novel environment (the open field), control and transgenic mice showed exploratory behavior. There were no statistically significant differences in motor activity or in the frequency of rearing, leaning, or grooming in the open field (p Ͼ 0.2 in all cases; Fig. 2 ). Freezing, a sign of great stress or anxiety, was not observed. During exploration, ACh release in the hippocampus was stimulated by up to 4-fold in control mice (Fig. 3A) . Maximum increases were slightly higher for control mice (343 Ϯ 59% of basal release) than for transgenic mice (278 Ϯ 47%), but the differences between these two time points or between the time courses did not reach significance (two-way ANOVA, F 1,252 ϭ 2.09; p ϭ 0.12). Whereas ACh levels increased, choline levels decreased in a mirror-like fashion to ACh and reached a minimum of 75 to 80% of basal levels after 30 min in both strains (data not shown).
On infusion of scopolamine, hippocampal ACh levels were increased more than 5-fold on average (Fig. 4B) . Again, maximum increases were slightly higher for control mice (665 Ϯ 144%) than for transgenic mice (594 Ϯ 123%), but differences between the two curves were a result of chance (two-way ANOVA, F 1,216 ϭ 0.05; p ϭ 0.83). During scopolamine infu- sion, choline levels were slightly reduced to 80 to 85% of basal levels in both mouse strains (data not shown). Glutamate and Glycerol. In microdialysates from untreated mice, basal levels of glutamate were 0.44 Ϯ 0.08 M in control mice and 0.20 Ϯ 0.04 M in transgenic APP SWE / PS1dE9 mice. After correction for recovery, extracellular glutamate levels were estimated at 1.99 and 0.90 M in controls and transgenic mice, respectively. This difference was significant (p ϭ 0.02; Table 1 ).
On exposure to the open field, brain extracellular glutamate concentrations increased slowly but steadily to approximately 150% of basal values (Fig. 4A) . In comparison, infusion of scopolamine caused a doubling of glutamate levels within 60 min (Fig. 4B) . Changes of glutamate levels were identical in the two mouse strains (p Ͼ 0.3).
Basal levels of glycerol were 1.23 Ϯ 0.40 M in control mice and 1.04 Ϯ 0.58 M in transgenic mice. After correction for recovery, extracellular glycerol levels were estimated at 9.4 and 8.9 M in controls and transgenic mice, respectively (p ϭ 0.74; Table 1 ). Glycerol levels did not appreciably change during either behavioral activation or scopolamine infusion (data not shown).
Energy Metabolites: Glucose and Lactate. In microdialysates from untreated mice, basal levels of glucose were 56.8 Ϯ 11.1 M in control mice (n ϭ 5) and 47.1 Ϯ 3.5 M in transgenic APP SWE /PS1dE9 mice (n ϭ 8). After correction for recovery, extracellular glucose levels were estimated at 0.9 and 0.76 mM in controls and transgenic mice, respectively (p ϭ 0.34; Table 1 ). Basal levels of lactate were 39.4 Ϯ 6.2 M in control mice and 27.1 Ϯ 3.5 M in transgenic mice, yielding true extracellular lactate levels of 0.43 and 0.30 mM in controls and transgenic mice, respectively. This difference was borderline significant (p ϭ 0.06; Table 1 ).
When mice were placed into the open field, glucose levels increased in a delayed fashion during exploration and remained elevated even after the mice had been put back into their home cages (Fig. 5A ). Extracellular concentrations of lactate increased rapidly by more than 2-fold during exploration but returned to normal within 2 h (Fig. 5B ). These metabolic responses were similar in both control and transgenic mice.
Infusion of scopolamine (1 M) caused a slow increase of 
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glucose levels that remained high after 3 h (Fig. 6A) . However, lactate levels were not affected by scopolamine (Fig.  6B ). No differences were noted between the two strains of mice (p Ͼ 0.5).
Discussion
Mouse models of AD present with variable degrees of amyloid peptide formation and amyloid deposition (McGowan et al., 2006) . For the present study, we chose a double transgenic mouse strain in which the Swedish APP mutation is expressed together with the presenilin-1 gene deleted in exon 9 (Borchelt et al., 1997; Jankowsky et al., 2004) . The PS-1 mutation specifically increases the formation of A␤42 peptide, which is highly amyloidogenic (Jankowsky et al., 2004) and causes the development of amyloid plaques early in life. Our finding of amyloid plaques in 10-to 14-month-old mice corresponds to an earlier report (Garcia-Alloza et al., 2006) , and the high A␤ 1-42 peptide levels observed in this previous study (approximately 1.0 nmol/g wet tissue, corresponding to 4.5 g/g) were confirmed in our measurements (6.6 g/g wet weight). In another study, a slightly lower value (2.2 g/g) was reported for hippocampal tissue of these animals (Liu et al., 2004 ). However, it should be noted that most of this A␤ 1-42 is "insoluble" peptide that was solubilized from tissue by guanidine (see under Materials and Methods).
Microdialysis is ideally suited to evaluate presynaptic cholinergic function in vivo because sampling of ACh in the extracellular fluid of the brain reflects the activity of central cholinergic fibers. In the present study, basic parameters of cholinergic function were largely preserved in APP SWE ϫ PS1dE9 mice, despite high A␤ 1-42 levels and amyloid deposits. Thus, the level of extracellular ACh in the hippocampus-representing the activity of septohippocampal cholinergic fibers-was almost identical in controls and transgenic mice (209 versus 193 nM, a reduction of Ͻ10%; p Ͼ 0.2). HACU activity, a measure of ACh turnover and cholinergic firing frequency, was unchanged in amyloid-bearing mice. AChE and butyrylcholinesterase activities were the same in both mouse strains. These findings are in line with an earlier study in which cholinergic markers were unchanged in these mice at 6 months of age and mildly decreased at age 18 months (Savonenko et al., 2005) .
The focus of our present work was to investigate changes of neurotransmitters and energy metabolites under conditions of behavioral and pharmacological stimulation. For this purpose, we first exposed the mice to an open field. Exploration of a novel environment is known to enhance hippocampal 
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ACh release (Kopf et al., 2001; Hartmann et al., 2004) , and this response was also observed in this study (Fig. 3A) . Our second paradigm of stimulation was an infusion of scopolamine, a muscarinic antagonist that increases ACh release by blocking presynaptic inhibitory autoreceptors of the muscarinic (M 2 /M 4 ) subtype. On scopolamine infusion, ACh release was strongly enhanced to 500 to 600% of basal levels (Fig. 3B) , whereas choline levels decreased (data not shown). Amyloid-bearing mice had similar cholinergic responses as control mice in both paradigms (Fig. 3, A and B) .
Although most studies in AD neurochemistry focused on cholinergic dysfunction, changes of glutamatergic function have also been repeatedly described early in AD. Glutamate concentrations are lowered in AD brains (Lowe et al., 1990) , and loss of glutamatergic neurons was suggested by reductions in vesicular glutamate transporters (Kirvell et al., 2006) . In contrast, excitotoxicity was postulated as a contributor to neurodegenerative diseases, and increased extracellular glutamate levels were postulated in AD brain (Hynd et al., 2004) . In our study, extracellular levels of glutamate were 2 M in control mice, a value that is similar to previous measurements in mice using microdialysis or enzyme electrodes (1-5 M; Hascup et al., 2008) . We were surprised to find that basal glutamate concentrations were significantly lower in transgenic mice (Table 1) , a finding that supports glutamatergic dysfunction in amyloid-bearing mice (Kirvell et al., 2006) but is at variance with the idea of ongoing cell death as a result of excitotoxicity. Moreover, both glycerol and choline are products of membrane breakdown (Marklund et al., 1997; Klein, 2000) , but neither was increased in the doubly transgenic mice (Table 1) ; thus, no obvious degeneration of brain cells occurred in these mice during the experimental phase.
Extracellular levels of glutamate, as sampled by microdialysis, are not easy to interpret because they are partially from nonvesicular sources and are affected by changes of glutamate release and uptake into glial cells (van der Zeyden et al., 2008) . In the present study, glutamate levels did not strongly respond to behavioral activation (Fig. 4A) ; however, they were increased in both strains by scopolamine (Fig. 4B ). This effect may be the result of an increase of ACh release evoked by scopolamine (Fig. 3B) or by the blockade of postsynaptic muscarinic receptors. Both mechanisms are possible because cholinergic activation increases glutamate levels in the striatum (via muscarinic receptors; Rawls and McGinty, 1998) and in the prefrontal cortex (via nicotinic receptors; Gioanni et al., 1999) , whereas in the hippocampus, glutamate release is inhibited by ACh acting on scopolaminesensitive M 2 -type muscarinic receptors (Marchi and Raiteri, 1989 ). Both mouse strains had similar responses for glutamate levels when expressed as relative changes of basal values (Fig. 4) , although the lower glutamate levels were preserved in transgenic mice when absolute changes of glutamate were graphed (data not shown); thus, our results are in agreement with reduced glutamate release in aged amyloid-bearing mice (Minkeviciene et al., 2008) .
In addition to neurotransmitters, we also measured extracellular levels of the energy metabolites glucose and lactate. Glucose is the standard fuel for brain energy production; in addition, it is a precursor of acetyl-CoA, and therefore of ACh synthesis, and ACh levels depend on glucose oxidation in periods of increased cholinergic activity (Ragozzino et al., 1996; Löffelholz and Klein, 2006) . AD patients show glucose hypometabolism early in the disease, and reductions of the cerebral metabolic rate of glucose correlate with disease severity (Blass et al., 2002; Mosconi et al., 2008) . Lactate is a product of ischemic metabolism in muscle, but in brain lactate is formed by astrocytes and supports neuronal function in periods of low glucose availability and high neuronal demand (Pellerin and Magistretti, 2004; Schurr, 2006) . In mice, extracellular levels of glucose were 0.7 to 1.0 mM in hippocampus, a value that corresponds closely to previous measurements in rats using the more sophisticated zero-net-flux method (McNay and Gold, 1999) . Lactate levels were 0.3 to 0.4 mM and were slightly lower in transgenic mice (p ϭ 0.06), a finding of potential significance that is presently unexplained.
Behavioral stimulation in the open field caused glucose levels to increase in a delayed fashion (Fig. 4A) . This observation may reflect an increase of blood sugar or of blood flow in the hippocampus because blood glucose, blood flow, and glucose uptake in the brain are tightly coupled (Messier and Gagnon, 1996; Löffelholz and Klein, 2006) . Compared with the small changes of glucose, extracellular lactate levels were immediately increased more than 2-fold on placing the animals into the open field (Fig. 5B) . As lactate is now recognized as fuel for neurons (Schurr, 2006) , this increase of lactate levels is probably a sign of increased energy demand in the hippocampus during exploration and spatial orientation. It is noteworthy that the extent of glucose and lactate mobilization was identical in transgenic and control mice (Fig. 5) , indicating that amyloid peptides and plaques do not hamper the ability of mouse brain to respond adequately to a physiological stimulus.
Pharmacological stimulation was induced by the infusion of scopolamine, which caused a strongly increased release of ACh (Fig. 3B) . However, it must be noted that scopolamine also blocks excitatory postsynaptic M 1 receptors and therefore inhibits cholinergic activation of hippocampal pyramidal cells. The increase of glucose concentrations that was observed in the hippocampus during scopolamine infusion (Fig.  6A ) may be the result of a reduced energy demand in hippocampus during blockade of excitatory cholinergic input. Similar increases of glucose were seen during anesthesia (Fellows et al., 1992) . This interpretation is in agreement with the fact that hippocampal lactate levels remained unaltered during scopolamine infusion (Fig. 6B) .
Summarizing, a double transgenic mouse strain with high levels of amyloid peptides in the brain and widespread amyloid plaque formation displays only subtle changes in hippocampal activity. Cholinergic parameters were largely unchanged, although transgenic mice had a slightly lower basal ACh concentration and a somewhat smaller response to the open field paradigm. Therefore, this study indicates that presynaptic cholinergic function is largely unchanged in amyloid-bearing mice. It should be noted that our results do not exclude potential interactions of amyloid peptides with postsynaptic cholinergic signaling; for example, A␤ peptides interfere with both nicotinic (Dineley et al., 2001; Abbott et al., 2008) and muscarinic signaling (Goto et al., 2008; Machová et al., 2008) , but these interactions were not addressed in the present study. It is noteworthy that basal glutamate levels were decreased in APP SWE /PS1dE9 mice, although the responses to stimulation were preserved. We also document significant and distinct changes of glucose and lactate levels jpet.aspetjournals.org on brain stimulation, but again transgenic mice had similar or identical responses as controls. We conclude that although amyloid peptide formation may be a required step for brain dysfunction in AD, it does not seem to be sufficient to induce impairments of brain metabolism and central cholinergic function. Additional factors are evidently required to model the full picture of neuronal dysfunction that is characteristic of human AD.
